The 3rd Annual Cell Engager Summit is the only industry-led meeting focused on developing multi-specific cell engaging therapies in liquid and solid tumor indications, accelerating early discovery innovation into the clinic.
You will walk away with the latest insights into how development teams are improving the therapeutic window for cell engagers in the solid tumor microenvironment by targeting tumor antigens (HER2, PSMA, etc) and modulating co-stimulatory receptors (CD137/4-1BB, CD28).
Join dozens of industry experts to:
- Learn how to optimize drug construct design, maximize potency and efficacy against efficacious tumor targets, and mitigate on-target/off-tumor toxicity
- Discover what clinical data is emerging from combination approaches with checkpoint inhibitors (PD-1, PD-L1)
- Improve treatment efficacy in your own candidate programs
- Effectively scale complicated manufacturing of multi-specific cell engagers and benchmark your drug candidates against other competing platforms e.g. chimeric antigen receptor (CAR) T cells and other bispecifics
With over 22 hours of content, one interactive workshop, and over 5 hours of networking, this is your best chance to harness the power of immune cell engagement to advance next-generation cancer treatments to market.